Abstract
We compared rifabutin susceptibility and rpoB mutations in 98 multi-drug-resistant strains of Mycobacterium tuberculosis (MDR-TB) by DNA sequencing and with a line probe assay using the commercially available INNO-LiPA Rif. TB kit (the LiPA). Our results indicated that rifabutin continues to remain active against MDR-TB strains harboring certain genetic alterations and also that the LiPA might be useful in identifying MDR-TB strains susceptible to rifabutin.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibiotics, Antitubercular / pharmacology
-
Bacterial Proteins / genetics*
-
DNA Mutational Analysis / methods
-
DNA-Directed RNA Polymerases
-
Drug Resistance, Multiple, Bacterial
-
Humans
-
Microbial Sensitivity Tests / methods
-
Mutation / genetics
-
Mycobacterium tuberculosis / drug effects*
-
Mycobacterium tuberculosis / genetics*
-
Nucleic Acid Hybridization / methods
-
Rifabutin / pharmacology*
-
Tuberculosis, Multidrug-Resistant / genetics*
-
Tuberculosis, Multidrug-Resistant / microbiology*
Substances
-
Antibiotics, Antitubercular
-
Bacterial Proteins
-
rpoB protein, Mycobacterium tuberculosis
-
Rifabutin
-
DNA-Directed RNA Polymerases